Disease Report: Ulcerative colitis

1. Disease Summary:

2. Global Prevalence and Disease Burden:

• UC affects millions worldwide, with increasing incidence in newly industrialized countries.
• The disease imposes a substantial health economic burden due to frequent hospitalizations, surgeries, long-term medication use, and productivity loss.
• UC leads to considerable disability and negatively impacts patients’ physical, psychological, and social well-being.
• Hospital discharge rates and emergency visits related to UC have increased over recent years in many countries (source: medRxiv data summarized in initial searches).
• The economic burden includes direct medical costs (medications, hospitalizations, surgeries) and indirect costs (work absenteeism, reduced productivity).

3. Unmet Medical Needs:

A. Treatment-Related Unmet Needs:

• Lack of a Definitive Cure: Current therapies control symptoms but do not cure UC or modify its natural history.
• Long-Term Efficacy: Many patients experience loss of response or inadequate response to existing therapies over time.
• Safety Concerns: Long-term safety profiles of immunosuppressants and biologics remain a concern, especially regarding infections and malignancies.
• Need for Mucosal Healing: Achieving and maintaining mucosal healing is critical for better long-term outcomes but remains challenging.
• Therapeutic Individualization: There is a need for personalized treatment strategies based on patient characteristics, disease severity, and response predictors.
• Limited Options for Refractory Disease: Patients who fail multiple therapies have few effective alternatives.
• Management of Acute Severe UC: Treatment options for acute severe flares are limited and often require hospitalization or surgery.

B. Monitoring and Risk Management:

• Optimized Disease Monitoring: Non-invasive, reliable biomarkers and imaging techniques are needed for tight disease control.
• Early Detection of Complications: Improved surveillance for dysplasia and colorectal cancer is necessary.
• Therapeutic Drug Monitoring (TDM): More widespread use of TDM could optimize biologic therapy dosing and improve outcomes.
• Risk Stratification: Better tools to predict disease course and treatment response are lacking.

C. Patient-Related Issues:

• Quality of Life (QoL): Physical symptoms, psychological distress, and social limitations significantly impair QoL.
• Psychological Support: Many patients suffer from anxiety, depression, and fatigue, which are often under-recognized and undertreated.
• Patient Education and Engagement: Enhanced patient involvement in treatment decisions and education about disease management is needed.
• Addressing Extraintestinal Manifestations: Effective management of associated conditions like arthritis, skin, and eye involvement is an unmet need.

4. Current Treatment Options:

• Aminosalicylates (5-ASA): First-line for mild-to-moderate UC; effective for induction and maintenance but limited in moderate-to-severe disease.
• Corticosteroids: Used for induction of remission in moderate-to-severe flares; not suitable for long-term use due to side effects.
• Immunomodulators (Azathioprine, 6-Mercaptopurine): Used for maintenance; slow onset and risk of toxicity.
• Biologics:
  • Anti-TNF agents (Infliximab, Adalimumab, Golimumab): Effective but with primary non-response and secondary loss of response in many patients.
  • Anti-integrin (Vedolizumab): Gut-selective with favorable safety but slower onset.
  • Anti-IL-12/23 (Ustekinumab): Approved for moderate-to-severe UC.
• Small Molecules:
  • Janus kinase (JAK) inhibitors (Tofacitinib): Oral option with rapid onset but safety concerns.
  • Sphingosine-1-phosphate receptor modulators (Etrasimod): Emerging oral therapies showing promise.
• Surgery: Colectomy remains a curative option but is associated with morbidity and impact on QoL.
• Supportive Care: Nutritional support, psychological counseling, and symptom management.

5. Current Clinical Trials:

• Trials investigating novel agents targeting different immune pathways (e.g., IL-23 inhibitors, JAK inhibitors, S1P modulators).
• Studies on combination therapies and personalized medicine approaches.
• Research on non-invasive biomarkers for disease monitoring.
• Trials focusing on improving mucosal healing and long-term remission.
• Investigations into therapies addressing extraintestinal manifestations and psychological symptoms.

6. Additional Context:

• The economic burden of UC is substantial, with costs driven by hospitalizations, surgeries, and biologic therapies.
• Patient-centered care models emphasizing shared decision-making and holistic management are increasingly recognized as essential.
• There is a growing emphasis on early intervention and treat-to-target strategies to improve outcomes.
• Despite advances, many patients remain undertreated or experience significant disease burden.

References:

• Daperno M, Armuzzi A, Danese S, et al. Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. Gastroenterol Res Pract. 2019;2019:3108025. doi:10.1155/2019/3108025. [PMID: 31565051] [PMC6745180] https://pubmed.ncbi.nlm.nih.gov/31565051/
• Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023 Apr 8. [PMID: 36871574]
• Additional sources from recent literature and clinical guidelines as summarized above.